GILENYA Drug Patent Profile

When do Gilenya patents expire, and when can generic versions of Gilenya launch?

Gilenya is a drug marketed by Novartis and is included in one NDA. There are two patents protecting this drug and two Paragraph IV challenges.

The generic ingredient in GILENYA is fingolimod hydrochloride. Twenty-two suppliers are listed for this compound. Additional details are available on the fingolimod hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Gilenya

A generic version of GILENYA was approved as fingolimod hydrochloride by BIOCON LTD on December 4^th, 2019.

Summary for GILENYA

US Patents:	2
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for GILENYA

Paragraph IV (Patent) Challenges for GILENYA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
GILENYA	Capsules	fingolimod hydrochloride	0.25 mg	022527	1	2018-07-19
GILENYA	Capsules	fingolimod hydrochloride	0.5 mg	022527	19	2014-09-22

US Patents and Regulatory Information for GILENYA

GILENYA is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	GILENYA	fingolimod hydrochloride	CAPSULE;ORAL	022527-002	May 11, 2018		RX	Yes	No					Y
Novartis	GILENYA	fingolimod hydrochloride	CAPSULE;ORAL	022527-001	Sep 21, 2010	AB	RX	Yes	Yes

International Patents for GILENYA

When does loss-of-exclusivity occur for GILENYA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Guatemala

Hong Kong

Hungary

Israel

Japan

Jordan

Lithuania

Malaysia

Mexico

Morocco

New Zealand

Peru

Poland

Portugal

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering GILENYA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2010101513
Australia	2010300918
Australia	2010300919

Supplementary Protection Certificates for GILENYA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1613288	91867	Luxembourg		91867, EXPIRES: 20260317
1613288	C01613288/01	Switzerland		PRODUCT NAME: FINGOLOMOD; REGISTRATION NO/DATE: SWISSMEDIC 60916 20110103
0627406	2011020	Ireland		PRODUCT: GILENYA FINGOLIMOD AND/OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF REGISTRATION NO/DATE: IRELAND EU/1/11/677/001, EU/1/11/677/002, EU/1/11/677/003, EU/1/11/677/004 / 17/03/2011; FIRST REGISTRATION NO/DATE: EUROPEAN UNION EU/1/11/677/001, EU/1/11/677/002, EU/1/11/677/003, EU/1/11/677/004 / 17/03/2011

Gilenya (fingolimod) Investment Scenario and Fundamentals Analysis: Patent/Exclusivity, Competitive Risk, and Revenue Outlook

Last updated: July 28, 2026

Gilenya is an established, oral multiple sclerosis (MS) therapy with a mature revenue base and shrinking pricing power as patent and exclusivity milestones approach. Near-term investment risk concentrates in (1) patent estate erosion and generic entry windows for fingolimod and branded dosing forms, (2) payer-driven switching within oral MS classes, and (3) competitive pressure from other high-penetration MS agents, including S1P receptor modulators and higher-efficacy monoclonal antibodies. The fundamental question for investors is not “is fingolimod viable,” but “how quickly do economics and market share compress as originator IP weakens and payer formularies move.”

What patents protect Gilenya (fingolimod) and how strong is the patent estate?

Patent coverage basics for fingolimod products

Featured snippet answer: Gilenya’s enforceable IP risk is driven by expiring composition and method-of-use patents on fingolimod and by the residual value of formulation, dosing, and process patents that can delay generic entry for specific dosage forms, strengths, or manufacturing processes. The key diligence step is mapping Orange Book listed patents to listed strengths and dosage forms and tying each patent to its likely generic infringement theory (ANDA or 505(b)(2) route).

How to structure a patent estate view for diligence

• Composition-of-matter patents: typically the primary value driver; once expired, the market moves quickly to generics unless other patents cover specific claims.
• Method-of-use patents: can delay entry if generics seek “label carving” and ANDA certifications cannot be cleared via carve-outs.
• Formulation/process patents: slower to enforce but can protect specific manufacturing steps or stability-related formulation attributes.
• Patent-term adjustments and extensions: can shift effective expiration dates; investors must model “effective exclusivity end” not just nominal filing timelines.

Where infringement pressure comes from after MDD expansion

S1P mechanism drugs in MS have high interchangeability in payer decisions. Even when a label-protected claim exists, generics often aim to launch with a carved label rather than litigate broad method-of-use assertions. For investors, this means enforcement effectiveness matters less than the practical ability of the originator to keep generics off the market for the commercially meaningful label.

Core investment implication

If the Orange Book patent list for Gilenya has limited “blocking” patents remaining for the key strengths, generic erosion will likely be fast and price-led. If method-of-use coverage is strong and enforceable for the full commercially relevant label, generic entry can be delayed but at the cost of likely settlement risk and payer response.

When does Gilenya lose exclusivity and what are the likely generic entry risks?

What dates matter most for exclusivity and generic timing?

Featured snippet answer: Market entry risk is determined by the earliest non-expired Orange Book patent that blocks ANDA approval for the key dosing strengths and by the timing of any exclusivity periods tied to labeling or pediatric/other statutory exclusivities. For a mature product like Gilenya, the commercial “last day” is usually the last blocking patent plus any applicable exclusivity extension.

Generic entry scenario modeling logic

A workable diligence framework for investment scenarios:

1. Identify the earliest “Type” certifications you expect from ANDA filers (Paragraph IV vs Paragraph III vs carve-out scenarios).
2. Model probability-weighted timelines:
   • Litigation-stayed approval (if a Paragraph IV is asserted and a stay is granted).
   • Immediate approval upon non-asserted or cleared patents.
3. Price erosion curve:
   • First generic entry typically compresses net price rapidly.
   • Follow-on entrants accelerate unit-cost pressure.

How many patents can still matter after generics begin?

Featured snippet answer: Investors should assume that once a first major blocking patent falls, subsequent remaining patents rarely stop generic entry entirely; they most often delay follow-on strengths or trigger settlements limited by claim scope. The investment takeaway is to treat the patent estate as a set of staged stopgaps rather than a single hard wall.

How does Gilenya compare with other oral MS drugs on competitive economics and payer preference?

S1P competitors and mechanism substitution risk

Featured snippet answer: Within MS, fingolimod competes in a crowded oral segment dominated by S1P receptor pathway agents and by higher-efficacy options moving into broader payer coverage. Substitution risk is highest where formularies favor lower administration burdens, favorable safety profiles, or superior efficacy in key subpopulations.

Practical substitution axes payers use

• Dosing convenience and adherence: once- or twice-daily regimens can dominate formulary design.
• Safety and monitoring burden: fingolimod requires first-dose monitoring; S1P competitors vary in risk management needs.
• Efficacy and endpoints: outcomes in relapsing forms and switching logic can drive preferred status.
• Switching policies: payers may push “step therapy” or “preferred agent” rules after a certain treatment line.

Monoclonal antibody pressure and long-term market share

Even if fingolimod maintains a base of patients, investors should model a gradual market share shift toward monoclonal antibodies where payers and treatment guidelines converge on higher-efficacy regimens. This can reduce growth even before generic entry.

What is the FDA and Orange Book status of Gilenya?

Orange Book listing role in litigation and ANDA risk

Featured snippet answer: The Orange Book is the gatekeeper for ANDA timing because it lists patents that are used for infringement certifications. For investment decisions, the key diligence artifact is the patent list by strength and dosage form, mapped to filing type and expiration dates, then assessed for “blocking” effect for generic approval.

FDA regulatory pathway considerations

Gilenya is marketed for MS under an FDA-approved label. From an investment lens, the risk is not only generic approval but also whether generics can launch with full label access or whether carve-outs reduce substitution and preserve originator revenue.

What generic entry risks exist for Gilenya by dosage form and strength?

Dosage form-specific risk mapping

Featured snippet answer: Generic risk is strength-specific. If Orange Book lists are not uniform across 0.25 mg vs other strengths, the earliest patent expiration can differ by strength, allowing “partial substitution” that still materially dents revenue.

“Launch, settle, or litigate” pathway choices

For investors, the generic entrant’s choice drives the commercial timeline:

• Straight litigation path: increases odds of a stay but prolongs uncertainty.
• Settlement and licensed entry: reduces litigation uncertainty but can cap authorized generic duration and delay “full margin collapse.”
• Non-asserted carve-out: can erode revenue faster if payer formularies accept the carved label.

What patent litigation affects Gilenya and how should it shape investment timing?

Litigation as a volatility driver

Featured snippet answer: For legacy MS small molecules, patent litigation typically drives a short-term volatility window around ANDA decisions, not a long-term protection of market share. The business question is “does litigation delay approval enough to preserve net present value.”

Settlement-driven scenarios

Settlement agreements can result in:

• Entry at a defined date (often earlier than full patent expiration).
• Authorized generic entry terms.
• Carve-out label restrictions or marketing limitations.

Investment modeling should treat settlements as a separate scenario from “full win in court.”

What formulation patents protect Gilenya and can they delay generic competition?

Formulation IP tends to be narrower than composition IP

Featured snippet answer: Formulation and process patents can delay or complicate generic manufacturing for specific dosage forms, but they rarely block generic entry for long when composition or method claims fall. Their commercial value depends on whether they are “blocking” on the Orange Book list for the key strengths.

Process and stability claims

If process patents are asserted, generics can design around manufacturing steps. Investors should model process patents as weaker than composition-of-matter patents, with higher likelihood of design-around and faster resolution through settlement.

What method-of-use patents could block or narrow generic approval?

Label protection vs practical payer substitution

Featured snippet answer: Even when method-of-use patents are asserted, generics can often seek label carve-outs. Investors should model that carve-outs reduce originator losses only if payers enforce the narrowed label and clinical practice refuses substitution.

Switching and clinical practice friction

If clinical practice supports switching to other agents, method-of-use carve-outs may have limited economic impact. The strongest label protection usually comes from “blocking patents” rather than narrow method claims.

Which companies are likely to challenge Gilenya and how does that map to licensing risk?

Challenger profile in mature small-molecule generics

Featured snippet answer: In a mature, high-volume branded oral drug, the likely challengers are established generic manufacturers with ANDA portfolios targeting oral solids and S1P pathway drugs. Investment relevance lies in whether a challenger is filing for a full-label generic or seeking carve-out.

Licensing and authorized generic outcomes

• If an originator licenses an entrant, the originator’s revenue usually shifts from brand to shared economics or delayed erosion.
• If no licensing occurs, aggressive price competition after first approval can compress margins rapidly.

Commercial fundamentals: what drives Gilenya’s revenue durability?

Revenue is driven by persistence, switching, and contracting

For mature oral MS drugs, top-line is a function of:

• Patient persistence (treatment continuation rates).
• Switching behavior (from other MS treatments into fingolimod and out of fingolimod into newer agents).
• Contracting and net price (rebates, discounts, and formulary placement).
• Generic erosion speed (timing of entry by strength).

Where the investment risk concentrates

1. Speed of net price compression upon generic entry.
2. Loss of formulary position due to payer preference for newer oral S1P agents or higher-efficacy biologics.
3. Ongoing safety and risk-management scrutiny affecting clinical uptake.

How does Gilenya compare with key MS peers on lifecycle stage?

Lifecycle stage framework

• Gilenya is in a late lifecycle category: high background penetration, limited patient expansion, reliance on persistence.
• Competitors include newer S1P agents and monoclonal antibodies with stronger payer pull and guideline momentum.

Competitive implications for investment

Even before generic entry, payer contracting can narrow incremental revenue. After generic entry, competitors’ “preferred agent” status accelerates substitution.

Regional considerations: where is generic and biosimilar risk most likely to show up first?

US-centric risk usually dominates for Orange Book and ANDA timing

Featured snippet answer: US patent and Orange Book status primarily determines the timing of generic erosion because it controls ANDA approval. International markets follow later through local regulatory pathways.

EU and other jurisdictions

For investors, non-US risks affect global revenue diversification but usually lag US timing. EU market access dynamics can differ based on local patent enforcement and pricing policy, but US remains the anchor for investor modeling when US remains the largest value component.

Key investment scenarios for Gilenya (probability-weighted view)

Scenario 1: Faster-than-expected generic erosion (high risk)

• Earliest blocking patents expire sooner than modeled or litigation resolves quickly.
• Paragraph IV outcomes favor challengers.
• Net price drops sharply after first generic launch by key strengths. Investment impact: margin compression plus share loss; valuation multiple compresses.

Scenario 2: Delayed generic entry via blocking patents or settlement (base case)

• Remaining Orange Book patents delay approval for a subset of strengths.
• Litigation or settlement pushes entry out by defined periods.
• Originator maintains formulary position temporarily due to slower erosion. Investment impact: cash flows remain resilient longer; still trending down.

Scenario 3: Sustained premium economics via strong enforcement or carve-outs (low risk)

• Enforceable blocking IP limits generic substitution to narrow label carve-outs.
• Payer systems do not accept the carved label at scale. Investment impact: slower revenue decline; longer duration optionality.

Key Takeaways

• Gilenya’s investment fundamentals hinge on patent blocking power tied to Orange Book listings by strength and dosage form, not on general “fingolimod IP.”
• Generic entry is the primary timeline risk; litigation and settlements typically shift timing more than they prevent long-run erosion.
• Even with IP protections, payer formularies and competitive substitution within oral MS therapies and toward monoclonal antibodies compress growth and can accelerate share loss.
• Investment modeling should use staged scenarios: first strength erosion, then full brand replacement, with net price compression curves layered over patient persistence assumptions.

FAQs

1) What is the biggest driver of Gilenya valuation risk: patent expiry or payer substitution?

Patent expiry controls generic entry timing; payer substitution controls how quickly patients move even before generics. Net valuation risk combines both, with generic erosion usually dominating the magnitude of cash flow compression.

2) What typically happens to Gilenya net price after the first generic launches?

Net price usually compresses rapidly as contracts reset and pharmacy and payer incentives shift toward lower acquisition cost, with margins eroding before patient persistence fully changes.

3) How do Paragraph IV challenges affect the timing of ANDA approvals for a legacy MS drug?

Paragraph IV challenges can trigger litigation stays if asserted properly and if statutory requirements are met; that delays approval and shifts the cash flow timeline.

4) Can label carve-outs preserve Gilenya revenue after generic entry begins?

Carve-outs can slow substitution only if payers enforce the narrowed eligibility and clinical practice declines switching. If payers treat fingolimod as therapeutically substitutable across the carved boundaries, revenue protection weakens.

5) Which competitors most threaten Gilenya share before patent expiration?

Competitors with strong payer adoption in relapsing MS, including newer S1P receptor modulators and higher-efficacy monoclonal antibodies, tend to pressure both formulary positioning and switching patterns.

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-07-28).
2. U.S. Food and Drug Administration. Drug Approval Packages and Labeling for Gilenya (fingolimod). (Accessed 2026-07-28).